Drug resistance pattern of HIV type 1 isolates sampled in 2007 from therapy-naive pregnant women in North-Central Nigeria

AIDS Research and Human Retroviruses

Volumn 28, Issue 1, 2012, Pages 115-118

  Ajoge, Hannah O ^a,b   Gordon, Michelle L ^b   Ibrahim, Sani ^a   Shittu, Oladapo S ^a   Ndung'u, Thumbi ^b   Olonitola, Stephen O ^a  

^a AHMADU BELLO UNIVERSITY   (Nigeria)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; DARUNAVIR; DELAVIRDINE; EFAVIRENZ; ETRAVIRINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; TIPRANAVIR;

ARTICLE; DNA POLYMORPHISM; FEMALE; GENE MUTATION; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; NIGERIA; NONHUMAN; NUCLEOTIDE SEQUENCE; PREGNANT WOMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS ISOLATION;

CASE-CONTROL STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV SEROPOSITIVITY; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; NIGERIA; PHYLOGENY; POLYMORPHISM, GENETIC; PREGNANCY;

EID: 84855591515     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0115     Document Type: Article

References (15)

1. Federal Ministry of Health: Technical Report, 2008 National HIV Sero-prevalence Sentinel Survey. Abuja, 2009, pp. 1-88.
2. Ajoge HO, Gordon ML, de Oliveira T, et al.: Genetic characteristics, coreceptor usage potential and evolution of Nigerian HIV-1 subtype G and CRF02-AG isolates. PLoS ONE 2011;6(3):e17865. doi:17810.11371/journal.pone .0017865.
3. Singh A, Page T, Moore PL, et al.: Functional and genetic analysis of coreceptor usage by dualtropic HIV-1 subtype C isolates. Virology 2009;393(1):56-67.
4. Oelrichs RB, Workman C, Laukkanen T, McCutchan FE, and Deacon NJ: A novel subtype A/G/J recombinant full-length HIV type 1 genome from Burkina Faso. AIDS Res Hum Retroviruses 1998;14(16):1495-1500. (Pubitemid 28507343)
5. Soares EA, Santos AF, Gonzalez LM, et al.: Mutation T74S in HIV-1 subtype B and C proteases resensitizes them to ritonavir and indinavir and confers fitness advantage. J Antimicrob Chemother 2009;64(5):938-944.
6. Turner D, Brenner B, Moisi D, et al.: Nucleotide and amino acid polymorphisms at drug resistance sites in non-Bsubtype variants of human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004;48(8):2993-2998. (Pubitemid 38989166)
7. De Meyer S, Vangeneugden T, van Baelen B, et al.: Resistance profile of darunavir: Combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses 2008;24(3): 379-388. (Pubitemid 351457745)
8. De Mendoza C, Morello J, Garcia-Gasco P, Rodriguez-Novoa S, and Soriano V: Tipranavir: A new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients. Expert Opin Pharmacother 2007;8(6):839-850. (Pubitemid 46744769)
9. Agwale SM, Zeh C, Paxinos E, et al.: Genotypic and phenotypic analyses of human immunodeficiency virus type 1 in antiretroviral drug-naive Nigerian patients. AIDS Res Hum Retroviruses 2006;22(1):22-26. (Pubitemid 43201513)
10. Ojesina AI, Sankalé JL, Odaibo G, et al.: Subtype-specific patterns in HIV type 1 reverse transcriptase and protease in Oyo State, Nigeria: Implications for drug resistance and host response. AIDS Res Hum Retroviruses 2006;22(8):770-779. (Pubitemid 44735004)
11. Holguin A, Paxinos E, Hertogs K, Womac C, and Soriano V: Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. J Clin Virol 2004;31(3):215-220. (Pubitemid 39311801)
12. Fleury HJ, Toni T, Lan NT, et al.: Susceptibility to antiretroviral drugs of CRF01-AE, CRF02-AG, and subtype C viruses from untreated patients of Africa and Asia: Comparative genotypic and phenotypic data. AIDS Res Hum Retroviruses 2006;22(4):357-366.
13. Reuman EC, Rhee SY, Holmes SP, and Shafer RW: Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations. J Antimicrob Chemother 2010;65(7):1477-1485.
14. Abimiku AG, Croxton T, Akintunde E, et al.: Experiences in establishing a PEPFAR-supported laboratory quality system in Nigeria. Am J Clin Pathol 2010;134(4):541-549.
15. Chan PA and Kantor R: Transmitted drug resistance in nonsubtype B HIV-1 infection. HIV Ther 2009;3(5):447-465.